An interventional study of Trier Social Stress Test in Mild Cognitive Impairment and Alzheimer Disease, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Cognitive Dysfunction by Johns Hopkins University — 13 open to participants now, 15 under way, 1 of them phase 3. Cognitive Dysfunction · Johns Hopkins University.
Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, this one is the 5th largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2023, is one of 22 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 22nd registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →13 of the 34 studies in Cognitive Dysfunction by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 65+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 60–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 65+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–100
Johns Hopkins University · Sites in United States
Ages 18–89
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 52 across the 33 interventional studies, 350 across the 1 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
7 of the studies in Cognitive Dysfunction by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05611918Johns Hopkins UniversityREpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study | 2026-12-31 |
| NCT07454824Johns Hopkins Universitye-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most | 2027-02-06 |
| NCT04123314Johns Hopkins UniversityPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease | 2027-06-30 |
| NCT06351540Johns Hopkins UniversityExamining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance | 2027-07-01 |
| NCT04765137Johns Hopkins UniversityEvaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment.
The main question[s] it aims to answer are:
Participants will have 3 in-person study visits. The first 2 will occur at baseline and the 3rd visit will occur 2 years later. During the visits, participants will provide blood and saliva samples, undergo a 10-minute social stress procedure, complete questionnaires, and take tests of memory and other thinking skills. Someone who knows the participant (a "study partner") will be asked questions about the participant's daily functioning at the first and 3rd study visits.
In the wake of discouraging results from treatment trials in Alzheimer's disease (AD), there is emerging consensus that the lack of efficacy in these trials is attributable to heterogeneity in the course of AD. Among the potential causes of heterogeneity, the investigators aim to focus on vulnerability to acute stress. Although associations between stress and the risk of AD are well established, these findings have not been used to inform AD intervention efforts. The investigators aim to address this crucial gap. Considering that in healthy individuals, acute stress can impair cognition in those who have risk factors for AD, the investigators propose that these individuals may represent a specific endophenotype who could be targeted for AD treatment trials. The investigators' prior findings implicate the endocrine stress response as an important component of AD risk that warrants further study.
The investigators aim to conduct a prospective study to examine the associations among the acute endocrine stress response, cognitive impairment following acute stress, and subsequent cognitive decline. For the investigators' basic study design, the investigators will induce acute stress with the Trier Social Stress Test (TSST; 5 minutes of public speaking and 5 minutes of mental arithmetic) and then administer a battery of cognitive tests. Two cognitive domains-memory and executive functioning-will be the primary cognitive outcomes. Salivary samples collected at fixed intervals will be used to measure stress hormone response; cortisol will the primary endocrine hormone outcome. The investigators will also examine the influence of apolipoprotein E (APOE) gene polymorphisms and polygenic risk scores, conduct sex-stratified analyses, and collect blood-based biomarkers for AD.
The investigators' study has 3 primary aims:
Secondary Aims: Conduct the analyses from Specific Aims 1-3 in men and women separately in order to identify sex-specific predictors of stress-induced memory and executive impairment and cognitive decline after 2 years. As an exploratory aim, the investigators will examine the influence of personality factors and stressful life events on the hypothesized associations.
For this study, participants will come to the clinic for 3 study visits. For the first visit, participants will be asked to bring someone who knows the participant well (a "study partner"). During that visit, participants and the participants' study partners will answer questions about the participant's daily functioning. In addition, participants (but not the participants study partners) will take paper-and-pencil tests and provide a blood sample. About one month later, participants will return for a second study visit, but the participants' study partner does not need to come to that visit. During that second visit, participants will undergo a brief procedure (public speaking and mental math) that is designed to cause stress, during which the investigators will measure participants' stress hormones by asking participants to provide the investigators with samples of the participants' saliva. Two years later, participants and the participants' study partners will return for Visit 3. At that visit, the investigators will ask participants to provide another blood sample and complete tests of memory and other thinking skills. Study partners will answer questions about the participants during this visit but will not take any tests or provide a blood sample.
Inclusion Criteria for Subjects with Mild Cognitive Impairment (MCI)
Exclusion Criteria for Subjects with MCI
Clinical and Cognitive Criteria for MCI due to AD
Inclusion Criteria for Study Partners
Exclusion Criteria for Study Partners
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in the study will get undergo the same stress procedure
Behavioral: Trier Social Stress Test
Acute psychosocial stress procedure; 5 minutes of public speaking and 5 minutes of mental arithmetic
Change in mean memory test composite score
Change in the mean composite score of the following memory tests: Neuropsychological Assessment Battery Word List Memory test, Morris Revision test, and a computerized Pattern Separation Task, with higher composite score indicating better memory
Time frame: Baseline and Visit 2 (up to 1 month) and Baseline to Visit 3 (up to 2 years)
Change in mean executive test composite score
Change in the mean composite score of the following executive tests: phonemic (letter) fluency test, part B of the Trial Making Test, and the backwards trial of a Digit Span task, with higher composite score indicating better executive functioning
Time frame: Baseline and Visit 2 (up to 1 month) and Baseline to Visit 3 (up to 2 years)
Change (in nanogram per liter; ng/L) in level of neurofilament light (NF-L)
Change in a blood biomarker of neurodegeneration, with higher levels indicating greater neurodegeneration
Time frame: Baseline to Visit 3 (up to 2 years)
Plan to share: Yes — Study investigators are committed to resource sharing, according to NIH policy. At the conclusion of the study, after the final freeze to the database, a public use database will be created and made available along with specifications for its use. Johns Hopkins University will share anonymized genomic sequence data by depositing these data in the database of Genotypes and Phenotypes (dbGaP) (a controlled-access database funded by NIH). In addition, the investigators will share data from biosamples (saliva and blood samples), including genotype data, at the time of publication of the primary results or within 9 months of database lock, whichever comes first. These data will be shared via the Alzheimer's Clinical Trials Consortium (ACTC), and/or the National Alzheimer's Coordinating Center (NACC).
Supporting information: Study protocol
Time frame: At time of publication of primary results or within 9 months of database lock, whichever comes first. No end data for data availability has been determined at this time.
Access criteria: Researchers at academic institutions are eligible.
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 60 months is above that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.